Published in Blood on January 01, 1998
Regulation of the germinal center gene program by interferon (IFN) regulatory factor 8/IFN consensus sequence-binding protein. J Exp Med (2005) 2.00
A mutation in the Icsbp1 gene causes susceptibility to infection and a chronic myeloid leukemia-like syndrome in BXH-2 mice. J Exp Med (2005) 1.74
AML1-ETO inhibits maturation of multiple lymphohematopoietic lineages and induces myeloblast transformation in synergy with ICSBP deficiency. J Exp Med (2002) 1.65
Expression profiling of CD34+ hematopoietic stem/ progenitor cells reveals distinct subtypes of therapy-related acute myeloid leukemia. Proc Natl Acad Sci U S A (2002) 1.57
Identification of target genes and a unique cis element regulated by IRF-8 in developing macrophages. Blood (2005) 1.44
Identification of 12/15-lipoxygenase as a suppressor of myeloproliferative disease. J Exp Med (2006) 1.37
Constitutive activation of SHP2 in mice cooperates with ICSBP deficiency to accelerate progression to acute myeloid leukemia. J Clin Invest (2008) 1.33
Regulation of apoptosis in myeloid cells by interferon consensus sequence-binding protein. J Exp Med (1999) 1.31
Epigenetic silencing of the oncogenic miR-17-92 cluster during PU.1-directed macrophage differentiation. EMBO J (2011) 1.30
Oncogenic signaling: new insights and controversies from chronic myeloid leukemia. J Exp Med (2007) 1.13
Infection-induced myelopoiesis during intracellular bacterial infection is critically dependent upon IFN-γ signaling. J Immunol (2010) 1.13
Disabled-2 is transcriptionally regulated by ICSBP and augments macrophage spreading and adhesion. EMBO J (2002) 1.10
Leukemia-associated, constitutively active mutants of SHP2 protein tyrosine phosphatase inhibit NF1 transcriptional activation by the interferon consensus sequence binding protein. Mol Cell Biol (2006) 1.07
Thioredoxin reductase mediates cell death effects of the combination of beta interferon and retinoic acid. Mol Cell Biol (1998) 1.06
IRF8 regulates acid ceramidase expression to mediate apoptosis and suppresses myelogeneous leukemia. Cancer Res (2011) 1.05
DNA methylation represses IFN-gamma-induced and signal transducer and activator of transcription 1-mediated IFN regulatory factor 8 activation in colon carcinoma cells. Mol Cancer Res (2008) 1.04
Interferon consensus sequence binding protein (ICSBP) decreases beta-catenin activity in myeloid cells by repressing GAS2 transcription. Mol Cell Biol (2010) 1.02
The IRF family of transcription factors: Inception, impact and implications in oncogenesis. Oncoimmunology (2012) 1.02
IRF-4 functions as a tumor suppressor in early B-cell development. Blood (2008) 1.01
The EBV Latent Antigen 3C Inhibits Apoptosis through Targeted Regulation of Interferon Regulatory Factors 4 and 8. PLoS Pathog (2013) 1.00
Rapid and sensitive detection of CpG-methylation using methyl-binding (MB)-PCR. Nucleic Acids Res (2006) 0.97
IFN regulatory factor 8 sensitizes soft tissue sarcoma cells to death receptor-initiated apoptosis via repression of FLICE-like protein expression. Cancer Res (2009) 0.96
Shared and distinct functions of the transcription factors IRF4 and IRF8 in myeloid cell development. PLoS One (2011) 0.95
Tumor-induced myeloid dysfunction and its implications for cancer immunotherapy. Cancer Immunol Immunother (2014) 0.94
A novel interferon regulatory factor (IRF), IRF-10, has a unique role in immune defense and is induced by the v-Rel oncoprotein. Mol Cell Biol (2002) 0.93
Down-regulation of interferon regulatory factor 4 gene expression in leukemic cells due to hypermethylation of CpG motifs in the promoter region. Nucleic Acids Res (2005) 0.91
Transcriptional and functional defects of dendritic cells derived from the MUTZ-3 leukaemia line. Immunology (2009) 0.90
Interferon regulatory factor 4 contributes to transformation of v-Rel-expressing fibroblasts. Mol Cell Biol (2001) 0.90
Differential requirement for irf8 in formation of embryonic and adult macrophages in zebrafish. PLoS One (2015) 0.88
Cytokine-induced tumor suppressors: a GRIM story. Cytokine (2010) 0.88
Tumor suppressive protein gene associated with retinoid-interferon-induced mortality (GRIM)-19 inhibits src-induced oncogenic transformation at multiple levels. Am J Pathol (2007) 0.86
The interferon consensus sequence binding protein (ICSBP/IRF8) activates transcription of the FANCF gene during myeloid differentiation. J Biol Chem (2009) 0.86
Fas-associated phosphatase 1 mediates Fas resistance in myeloid progenitor cells expressing the Bcr-abl oncogene. Leuk Lymphoma (2012) 0.86
Cross talk between Wnt/β-catenin and Irf8 in leukemia progression and drug resistance. J Exp Med (2013) 0.85
Monoallelic loss of tumor suppressor GRIM-19 promotes tumorigenesis in mice. Proc Natl Acad Sci U S A (2013) 0.85
ICSBP-mediated immune protection against BCR-ABL-induced leukemia requires the CCL6 and CCL9 chemokines. Blood (2009) 0.84
Regulation of telomerase activity by interferon regulatory factors 4 and 8 in immune cells. Mol Cell Biol (2008) 0.83
Regulation of the interferon regulatory factor-8 (IRF-8) tumor suppressor gene by the signal transducer and activator of transcription 5 (STAT5) transcription factor in chronic myeloid leukemia. J Biol Chem (2014) 0.82
Fas-associated phosphatase 1 (Fap1) influences βcatenin activity in myeloid progenitor cells expressing the Bcr-abl oncogene. J Biol Chem (2013) 0.82
Interferon consensus sequence-binding protein (ICSBP) promotes epithelial-to-mesenchymal transition (EMT)-like phenomena, cell-motility, and invasion via TGF-β signaling in U2OS cells. Cell Death Dis (2014) 0.82
The leukemia-associated fusion protein Tel-platelet-derived growth factor receptor β (Tel-PdgfRβ) inhibits transcriptional repression of PTPN13 gene by interferon consensus sequence binding protein (Icsbp). J Biol Chem (2012) 0.82
The role of Fas-associated phosphatase 1 in leukemia stem cell persistence during tyrosine kinase inhibitor treatment of chronic myeloid leukemia. Leukemia (2016) 0.81
LSK derived LSK- cells have a high apoptotic rate related to survival regulation of hematopoietic and leukemic stem cells. PLoS One (2012) 0.81
Polymorphisms in microRNA target sites modulate risk of lymphoblastic and myeloid leukemias and affect microRNA binding. J Hematol Oncol (2014) 0.81
Implication of IRF4 aberrant gene expression in the acute leukemias of childhood. PLoS One (2013) 0.80
Constitutive IRF8 expression inhibits AML by activation of repressed immune response signaling. Leukemia (2014) 0.80
A STATus report on DC development. J Leukoc Biol (2012) 0.79
Interferon regulatory factor-8 is important for histone deacetylase inhibitor-mediated antitumor activity. PLoS One (2012) 0.79
Relevance of Interferon Regulatory Factor-8 Expression in Myeloid-Tumor Interactions. J Interferon Cytokine Res (2016) 0.79
Design and Structural Requirements of the Potent and Safe TLR-9 Agonistic Immunomodulator MGN1703. Nucleic Acid Ther (2015) 0.78
The prognostic significance of IRF8 transcripts in adult patients with acute myeloid leukemia. PLoS One (2013) 0.78
MMP3-mediated tumor progression is controlled transcriptionally by a novel IRF8-MMP3 interaction. Oncotarget (2015) 0.76
Constitutive activation of SHP2 protein tyrosine phosphatase inhibits ICSBP-induced transcription of the gene encoding gp91PHOX during myeloid differentiation. J Leukoc Biol (2007) 0.76
Aberrant methylation and silencing of IRF8 expression in non-small cell lung cancer. Oncol Lett (2014) 0.76
GRIM-19: A Double-edged Sword that Regulates Anti-Tumor and Innate Immune Responses. Transl Oncogenomics (2008) 0.76
Bcr-abl regulates Stat5 through Shp2, the interferon consensus sequence binding protein (Icsbp/Irf8), growth arrest specific 2 (Gas2) and calpain. Oncotarget (2016) 0.75
Decreased calpain activity in chronic myeloid leukemia impairs apoptosis by increasing survivin in myeloid progenitors and xiap1 in differentiating granulocytes. Oncotarget (2017) 0.75
Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene. Cell (1993) 11.95
Skyrmion lattice in a chiral magnet. Science (2009) 8.83
Regression of primary gastric lymphoma of mucosa-associated lymphoid tissue type after cure of Helicobacter pylori infection. MALT Lymphoma Study Group. Lancet (1995) 6.32
Development and function of T cells in mice rendered interleukin-2 deficient by gene targeting. Nature (1991) 5.51
Immunodeficiency and chronic myelogenous leukemia-like syndrome in mice with a targeted mutation of the ICSBP gene. Cell (1996) 4.74
Functional significance of cell volume regulatory mechanisms. Physiol Rev (1998) 4.59
Plasmablastic lymphomas of the oral cavity: a new entity associated with the human immunodeficiency virus infection. Blood (1997) 4.36
Propagation of both parental mitochondrial DNAs in rat-human and mouse-human hybrid cells. J Mol Biol (1973) 3.93
Cancer mortality among workers in chemical plant contaminated with dioxin. Lancet (1991) 3.87
Spin transfer torques in MnSi at ultralow current densities. Science (2010) 3.64
axl, a transforming gene isolated from primary human myeloid leukemia cells, encodes a novel receptor tyrosine kinase. Mol Cell Biol (1991) 3.57
Generalized autoimmune disease in interleukin-2-deficient mice is triggered by an uncontrolled activation and proliferation of CD4+ T cells. Eur J Immunol (1995) 3.34
Cure of Helicobacter pylori infection and duration of remission of low-grade gastric mucosa-associated lymphoid tissue lymphoma. J Natl Cancer Inst (1997) 3.30
Immune responses in interleukin-2-deficient mice. Science (1993) 3.29
Regulation of scavenger receptor CD163 expression in human monocytes and macrophages by pro- and antiinflammatory stimuli. J Leukoc Biol (2000) 3.24
Frameshift mutants of beta amyloid precursor protein and ubiquitin-B in Alzheimer's and Down patients. Science (1998) 3.21
Subacute sclerosing panencephalitis: isolation of suppressed measles virus from lymph node biopsies. Science (1971) 3.07
Is alpha/beta for prostate tumors really low? Int J Radiat Oncol Biol Phys (2001) 2.94
Clinical experiences with magnetic drug targeting: a phase I study with 4'-epidoxorubicin in 14 patients with advanced solid tumors. Cancer Res (1996) 2.86
Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). Leukemia (2012) 2.78
Problems with interphase fluorescence in situ hybridization in detecting BCR/ABL-positive cells in some patients using a novel technique with extra signals. Cancer Genet Cytogenet (2001) 2.57
ras oncogene activation and occupational exposures in acute myeloid leukemia. J Natl Cancer Inst (1992) 2.54
Prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancer. J Clin Oncol (1999) 2.38
Chromatin structure is required to block transcription of the methylated herpes simplex virus thymidine kinase gene. Proc Natl Acad Sci U S A (1987) 2.35
Preclinical experiences with magnetic drug targeting: tolerance and efficacy. Cancer Res (1996) 2.35
Prevention of high-altitude pulmonary edema by nifedipine. N Engl J Med (1991) 2.34
Exposure to polychlorinated dioxins and furans (PCDD/F) and mortality in a cohort of workers from a herbicide-producing plant in Hamburg, Federal Republic of Germany. Am J Epidemiol (1995) 2.25
Clonality and X-inactivation patterns in hematopoietic cell populations detected by the highly informative M27 beta DNA probe. Blood (1994) 2.24
Different beta-subunits determine G-protein interaction with transmembrane receptors. Nature (1992) 2.23
Multicenter study of the European Assessment Group for Lysis in the Eye (EAGLE) for the treatment of central retinal artery occlusion: design issues and implications. EAGLE Study report no. 1 : EAGLE Study report no. 1. Graefes Arch Clin Exp Ophthalmol (2005) 2.19
Assignment of G-protein subtypes to specific receptors inducing inhibition of calcium currents. Nature (1991) 2.15
Angiotensin II activates nuclear transcription factor kappaB through AT(1) and AT(2) in vascular smooth muscle cells: molecular mechanisms. Circ Res (2000) 2.12
Gene variants of the bactericidal/permeability increasing protein and lipopolysaccharide binding protein in sepsis patients: gender-specific genetic predisposition to sepsis. Crit Care Med (2001) 2.06
Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cells. Exp Hematol (1993) 2.02
The CREATE project: development of certified reference materials for allergenic products and validation of methods for their quantification. Allergy (2008) 1.96
Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group. J Clin Oncol (2003) 1.86
IL-2-deficient mice raised under germfree conditions develop delayed mild focal intestinal inflammation. Am J Physiol (1999) 1.83
A phase relationship associates tRNA structural gene sequences with nucleosome cores. Cell (1979) 1.83
Crucial role of interferon consensus sequence binding protein, but neither of interferon regulatory factor 1 nor of nitric oxide synthesis for protection against murine listeriosis. J Exp Med (1997) 1.77
Helicobacter heilmannii-associated primary gastric low-grade MALT lymphoma: complete remission after curing the infection. Gastroenterology (2000) 1.76
Regression of gastric MALT lymphoma after eradication of Helicobacter pylori is predicted by endosonographic staging. MALT Lymphoma Study Group. Gastroenterology (1997) 1.75
Buccal swabs but not mouthwash samples can be used to obtain pretransplant DNA fingerprints from recipients of allogeneic bone marrow transplants. Bone Marrow Transplant (2000) 1.72
Selectivity in signal transduction determined by gamma subunits of heterotrimeric G proteins. Science (1993) 1.71
Ion channels in cell proliferation and apoptotic cell death. J Membr Biol (2005) 1.69
Helicobacter and gastric MALT lymphoma. Gut (2002) 1.66
Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial. Leukemia (2011) 1.64
Hepatorenal reflex regulating kidney function. Hepatology (1991) 1.61
Rapid quantification of mixed chimerism using multiplex amplification of short tandem repeat markers and fluorescence detection. Bone Marrow Transplant (1999) 1.61
Kinetics of the graft-versus-leukemia response after donor leukocyte infusions for relapsed chronic myeloid leukemia after allogeneic bone marrow transplantation. Blood (1998) 1.59
Object-oriented sequence analysis: SCL--a C++ class library. Comput Appl Biosci (1996) 1.58
Development and proliferation of lymphocytes in mice deficient for both interleukins-2 and -4. Eur J Immunol (1994) 1.57
Family of middle repetitive DNA sequences in the mouse genome with structural features of solitary retroviral long terminal repeats. Proc Natl Acad Sci U S A (1983) 1.54
Marked increase of the growth factors pleiotrophin and fibroblast growth factor-2 in serum of testicular cancer patients. Ann Oncol (2003) 1.53
Imatinib mesylate and nilotinib (AMN107) exhibit high-affinity interaction with ABCG2 on primitive hematopoietic stem cells. Leukemia (2007) 1.52
Monoclonal antibody FMC7 detects a conformational epitope on the CD20 molecule: evidence from phenotyping after rituxan therapy and transfectant cell analyses. Cytometry (2001) 1.52
Omeprazole-induced pseudohypertrophy of gastric parietal cells. Z Gastroenterol (1992) 1.51
Megakaryocyte hyperplasia and enhanced agonist-induced platelet activation in vasodilator-stimulated phosphoprotein knockout mice. Proc Natl Acad Sci U S A (1999) 1.50
SETBP1 mutation analysis in 944 patients with MDS and AML. Leukemia (2013) 1.50
Simple and sensitive detection of mutations in the ras proto-oncogenes using PNA-mediated PCR clamping. Nucleic Acids Res (1996) 1.49
Altered development and cytokine responses of myeloid progenitors in the absence of transcription factor, interferon consensus sequence binding protein. Blood (1999) 1.49
Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development. Leukemia (2005) 1.48
Ventricular laceration and cardiac tamponade during laparoscopic Nissen fundoplication. Surg Laparosc Endosc (1996) 1.48
Increased sitosterol absorption, decreased removal, and expanded body pools compensate for reduced cholesterol synthesis in sitosterolemia with xanthomatosis. J Lipid Res (1989) 1.47
Progressive encephalopathy and myopathy in transgenic mice expressing human foamy virus genes. Science (1991) 1.46
Phase I clinical study applying autologous immunological effector cells transfected with the interleukin-2 gene in patients with metastatic renal cancer, colorectal cancer and lymphoma. Br J Cancer (1999) 1.44
Protection against FIV challenge infection by genetic vaccination using minimalistic DNA constructs for FIV env gene and feline IL-12 expression. AIDS (2000) 1.44
Targeted inactivation of the tetraspanin CD37 impairs T-cell-dependent B-cell response under suboptimal costimulatory conditions. Mol Cell Biol (2000) 1.44
Lethal atherosclerosis associated with abnormal plasma and tissue sterol composition in sitosterolemia with xanthomatosis. J Lipid Res (1985) 1.43
Selective susceptibility of CD34-expressing cells to acquire flow cytometric features of apoptosis/necrosis on exposure to an ammonium chloride-based red blood cell lysing reagent. J Hematother (1998) 1.42
Interference of blood leucocytes in the measurements of immature red cells (reticulocytes) by two different (semi-) automated flow-cytometry technologies. Clin Lab Haematol (1996) 1.42
The equine herpesvirus 1 glycoprotein gp21/22a, the herpes simplex virus type 1 gM homolog, is involved in virus penetration and cell-to-cell spread of virions. J Virol (1996) 1.41
Subtypes of T-cell chronic lymphatic leukemia. Cancer (1983) 1.39
Images in cardiovascular medicine. Idiopathic hypereosinophilic vasculitis. Circulation (1995) 1.39
[Frequency, pattern and differential diagnosis of echogenic splenic changes: sonographic follow-up study]. Ultraschall Med (2000) 1.38
The synthesis of poxvirus-specific RNA in interferon-treated cells. Virology (1972) 1.38
Isolation of oligonucleosomes from active chromatin using HMG17-specific monoclonal antibodies. Nucleic Acids Res (1986) 1.38
Sensitivity of multidrug-resistant tumor cell lines to immunologic effector cells. Cell Immunol (1996) 1.38
Paclitaxel as weekly second-line therapy in patients with advanced pancreatic carcinoma. Anticancer Drugs (2000) 1.37
Highly sensitive and specific fluorescence reverse transcription-PCR assay for the pseudogene-free detection of beta-actin transcripts as quantitative reference. Clin Chem (1999) 1.35
Helicobacter pylori and gastric cancer:current status of the Austrain Czech German gastric cancer prevention trial (PRISMA Study). World J Gastroenterol (2001) 1.35
Complete remission of primary high-grade B-cell gastric lymphoma after cure of Helicobacter pylori infection. J Clin Oncol (2001) 1.34